The USF Diabetes and Endocrinology Center is an international leader in diabetes research. Our program’s goals are to help patients and their families by investigating ways to prevent or delay the onset of Type 1 and Type 2 diabetes, identify at-risk individuals’ years before clinical symptoms occur and to test cutting edge new therapies for those living with diabetes.

Currently Enrolling T1D Studies

TrialNet Pathway to Prevention Study

• For individuals between the ages of 1-45 years with a first-degree relative (parent, child, sibling) with type 1 diabetes
• For individuals between the ages of 1-20 years with a second-degree relative (grandparent, aunt, uncle, niece, nephew, cousin or half-sibling) with type 1 diabetes

Purpose:  To identify individuals at-risk for T1D and offer close monitoring for disease progression as well as potential prevention study opportunities.

For more information visit TrialNet on the web. 

Study Contact:  Juanita O'Brian, jobrian@health.usf.edu or (813) 974-9817

TrialNet Abatacept T1D Prevention Study

• For individuals > 6 years old
• Positive for two or more diabetes-related auto-antibodies
• Normal Glucose Tolerance

Purpose:  To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Contact: Emily Eyth, MSN, RN, CDE  emilyeyth@health.usf.edu or (813) 974-2793

TrialNet Hydroxychloroquine T1D Prevention Study

• For individuals > 3 years old
• Positive for two or more diabetes-related auto-antibodies
• Normal Glucose Tolerance

Purpose: To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Contact:  Emily Eyth, MSN, RN, CDE emilyeyth@health.usf.edu or (813) 974-2793

Intrexon T1D New Onset Study

• For individuals > 12 years old
• Diagnosed with Type 1 Diabetes within 150 days

Purpose: To preserve insulin production by preventing beta cell destruction in individuals newly diagnosed with T1D.

Study Contact: Emily Eyth, MSN, RN, CDE emilyeyth@health.usf.edu or (813) 974-2793

AFREZZA rapid acting inhaled insulin study for T1D Pediatric Patients

• For individuals ages 8-12 years old
• Diagnosed with T1D for > 1 year
• Not on a pump or willing to come off the pump for the study duration (up to 16 weeks).

Purpose: To test the safety and efficacy of Afrezza rapid acting inhaled insulin in T1D pediatric patients.

Study Contact:  Allison Castro, BS, RN castro@health.usf.edu or (813) 974-6139

Currently Enrolling T2D Studies

Takeda Type 2 Treatment Study (Alogliptin) for Pediatric Patients

• For individuals ages 10-17
• Diagnosed with type 2 diabetes
• Additional eligibility criteria will be reviewed with you by the study coordinator

Purpose: To test the safety and effectiveness of Alogliptin (FDA approved for treatment of type 2 adults) in pediatric type 2 patients.

Study Contact: Emily Eyth, MSN, RN, CDE  emilyeyth@health.usf.edu or (813) 974-2793

Boehringer Ingelheim Type 2 Treatment Study (Linagliptin and Empagliflozin) for Pediatric Patients

• For individuals ages 10-17
• Diagnosed with type 2 diabetes for at least 12 weeks
• Additional eligibility criteria will be reviewed with you by the study coordinator

Purpose: To test the safety and effectiveness of Linagliptin in combination with Empagliflozin (FDA approved for treatment of type 2 adults) in pediatric type 2 patients.

Study Contact: Allison Castro, BS, RN  castro@health.usf.edu  or (813) 974-6139